We have achieved the Dun & Bradstreet 5A1 rating, confirming our exceptional financial strength and minimal business risk. For our partners, this excellent rating is confirmation that we are a financially reliable company with the stability to invest for the long term, launch innovative therapies, support large-scale business transitions, and seamlessly take over established portfolios when affiliates exit the region or business models evolve. It also means having the operational strength to manage complex market access projects and ensure uninterrupted supply across 19 countries.
"This excellent rating from one of the world's most respected and longest-standing independent rating agencies, Dun & Bradstreet, is an important recognition for us. It proves that we are a company of exceptional financial strength and minimal business risk to work with," said Erna Slana, CFO of Medis and Member of the Management Board.
"Financial strength is one of the reasons why global pharmaceutical and biotech companies continue to choose us as their trusted partner across Central and Eastern Europe. Lasting partnerships are built not only on expertise, but also on reliability. We have been doing so for 38 years, delivering long-term commitments and successfully navigating one of the world's most diverse and complex healthcare markets."
